BioNTech and Pfizer have said a three-shot course of their Covid-19 vaccine was able to neutralise the new Omicron variant in a laboratory test.
The companies added that they could deliver an Omicron-based vaccine in March 2022 if needed. In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralising antibodies, but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.
Blood obtained from people that had their third booster shot a month ago neutralised the Omicron variant about as effectively as blood after two doses fought off the original virus. "Ensuring as